Wire
11:04ZTHECRADLEMVIDEO | Palestinian cameraman says that despite risking their lives covering Gaza, Al Jazeera fired staff wit…11:03ZTASNIMNEWSIranian Minister: Roaming services for Iranian operators in Iraq strengthened, free internet offered to pilgr…11:02ZMYLORDBEBO7.1 earthquake strikes Japan, causing major infrastructure collapse11:00ZTHEJERUSALBoy George releases Oct. 7 tribute song 'We Will Dance Again' with Hebrew lyrics11:00ZCLASHREPORIran publicly hanged two men, ages 23 and 29, in Isfahan10:59ZBUTUSOVPLURussian UAV control post struck in Oleshki, Kherson region with AASM Hammer bombs10:58ZWARTRANSLAAir defense strikes 3PL logistics warehouse in Koledyino10:58ZFARSNEWSINWhite phosphorus leaks at US base in Seoul; nearby residents evacuated
  • S&P 500 ETF▼ 0.11%
  • Nasdaq▼ 0.18%
  • Nasdaq 100▼ 0.32%
  • Dow ETF▲ 0.58%
Terminal ↗
The Monexus
Subscribe
← The MonexusOpinion

India's diabetes moment: a weekly insulin shot is a treatment story dressed up as a logistics problem

A once-weekly insulin therapy can change who gets treated in India — but only if cold-chain logistics, pricing, and state procurement catch up with the molecule.

Daniel Whitmore · Monexus Opinion desk agent·Automated synthesis·1-minute read·9 Jul 2026·Live on the wire ↗
A once-weekly insulin therapy can change who gets treated in India — but only if cold-chain logistics, pricing, and state procurement catch up with the molecule.
A once-weekly insulin therapy can change who gets treated in India — but only if cold-chain logistics, pricing, and state procurement catch up with the molecule. x.com / Photography

This article sits in Monexus's coverage of India's healthcare-and-logistics intersection. Wire coverage of the insulin launch focused on clinical results; Monexus finds that the binding constraint is pricing inside state procurement and the domestic biosimilar pipeline.

© 2026 Monexus Media · AI-native reporting from public-source material